CMS Finalizes 2027 Medicare Outpatient Payment Changes

CMS Finalizes 2027 Medicare Outpatient Payment Changes
Senior reviewing a Medicare bill beside a hospital outpatient clinic and prescription drug vial

The Centers for Medicare & Medicaid Services has finalized a broad set of 2027 Medicare outpatient payment changes that the agency says will lower some patient costs while redirecting billions of dollars in hospital payments. The rule, issued November 4, changes how Medicare pays for certain drugs bought through the 340B program, expands lower “site-neutral” payments for some imaging services and moves hundreds of procedures toward outpatient care.

The policy matters beyond the technical Medicare payment system. It could change the revenue mix for safety-net hospitals, alter incentives for hospitals to acquire physician practices and affect what some beneficiaries pay depending on where they receive care. The rule takes effect for calendar year 2027, so its savings figures are estimates rather than results already observed.

Facts: What CMS finalized

CMS’s official fact sheet says the rule updates payment policies for about 3,500 hospitals and 6,400 ambulatory surgical centers. For hospitals and surgery centers that meet applicable quality-reporting requirements, the annual payment update is 2.3%. That reflects a projected 3.2% market-basket increase less a 0.9 percentage-point productivity adjustment.

The most consequential change concerns 340B-acquired drugs. The 340B program requires participating drug manufacturers to sell outpatient medicines at discounts to eligible hospitals and other providers that serve low-income or otherwise underserved patients. Medicare has generally paid hospitals the drug’s average sales price, or ASP, plus 6% under the outpatient prospective payment system. CMS will instead pay for qualifying 340B-acquired drugs at ASP minus 28% in 2027, using a hospital acquisition-cost survey and other statutory authority.

CMS estimates that the new rate will reduce Original Medicare drug spending by $4.35 billion and beneficiary drug payments by $1.1 billion in its first year. That is a projected $5.45 billion reduction in total drug spending in 2027. The agency says a beneficiary receiving a qualifying drug in a hospital outpatient department could save an average of $900. Those are estimates, not a guarantee for every patient or hospital.

Federal law requires the outpatient payment system to remain budget neutral in the aggregate. In practical terms, CMS says the lower drug payments will be offset by higher payments for non-drug outpatient services. The rule also raises an existing offset that recovers earlier 340B-related payment increases: the reduction to the non-drug payment factor rises from 0.5% to 2% for affected hospitals, with CMS estimating that the recovery of $7.8 billion will be completed around 2031.

A second major change applies physician-office-equivalent rates to certain imaging without contrast at excepted off-campus hospital departments. The affected services include some X-rays, ultrasounds, bone-density scans, CT scans and MRIs. CMS estimates the policy will reduce Part B spending by about $190 million and beneficiary premiums by about $70 million in 2027. It also projects roughly $70 million in lower first-year beneficiary cost sharing.

The rule continues a three-year phaseout of Medicare’s “Inpatient Only” list. CMS is removing 637 services from the list for 2027, allowing clinically appropriate procedures to be paid in outpatient settings. It is also expanding the ambulatory surgical center covered-procedure list by several hundred services. The changes may lower cost sharing, but they do not require every procedure to be performed outside a hospital.

The rule includes other changes. CMS adds eight botulinum-toxin injection codes to prior authorization after reporting a 42.8% increase in hospital outpatient claims for the codes between 2017 and 2024. It also permits certain CMS-approved hospital accreditors to assess specified Emergency Medical Treatment and Labor Act administrative requirements during routine surveys.

Analysis: Why hospitals and beneficiaries may see different effects

The basic policy argument is that Medicare should not pay more for a drug than is justified by the hospital’s acquisition cost, particularly when the hospital bought the drug at a statutory discount. CMS says its survey found that 340B acquisition costs were substantially below ASP and that, in some cases, a beneficiary’s 20% coinsurance exceeded what the hospital paid. The administration presents the rule as a way to pass more of the discount through to patients and taxpayers.

Independent analysts agree that the payment shift is large but differ on its likely distribution. In its analysis of the earlier proposal, the KFF noted that budget neutrality would redistribute money from 340B drug payments into non-drug services. KFF warned that safety-net hospitals could lose revenue even as non-340B and for-profit hospitals gain from higher non-drug rates. That analysis covered the proposal, not the final rule, so its exact projected percentages should not be treated as the final outcome.

A separate Paragon Institute analysis said the final ASP-minus-28% rate is less severe than the deeper reduction suggested by CMS’s survey, while still reducing a Medicare payment margin that can encourage hospital consolidation. Paragon also said the new imaging policy could reduce incentives for hospitals to acquire physician practices solely to obtain higher facility payments. That is an interpretation of likely effects, not a measured result from the 2027 rule.

The budget-neutral structure also complicates the affordability message. A patient who receives a qualifying 340B drug may pay less, but another Medicare beneficiary using non-drug outpatient services could face higher cost sharing tied to the offsetting payment increases. Actual effects will depend on the service, the site of care, a beneficiary’s coinsurance and how hospitals respond.

What remains uncertain

The rule is final, but its real-world consequences are not. CMS’s savings estimates depend on utilization, drug prices, hospital billing and the operation of budget-neutral adjustments in 2027. Hospitals may change where they provide services, how they negotiate drug purchases or how they organize outpatient care. Safety-net hospitals and rural providers may not be affected in the same way: CMS’s materials identify exemptions for some rural sole-community hospitals and other categories in parts of the payment policy.

The imaging and surgery provisions also preserve clinical judgment. Moving a service off the inpatient-only list makes outpatient payment possible; it does not mean that every patient is suitable for outpatient treatment. Prior authorization for selected botulinum-toxin codes does not eliminate coverage for medically necessary treatment when documentation supports it.

As of November 15, 2026. The verified development is a finalized CMS rule scheduled to govern Medicare outpatient payments in 2027. The agency’s savings claims remain projections, and effects on hospitals, premiums and patient bills will become clearer after implementation.

Sources

Advertisement

Filed under:

Keep reading